The Effect of Roflumilast on Absolute Neutrophil Count, MMP-9 Serum, % VEP1 Value, and CAT Scores in Stable COPD Patients
DOI:
https://doi.org/10.36497/jri.v42i2.265Keywords:
COPDAbstract
Background: Chronic obstructive pulmonary disease is the leading cause morbidity and mortality worldwide. Cigarette smoke and noxious agent causing oxidative stress activated nuclear factor-κB then increase inflammatory cell releases. Roflumilast have antiiinflammatory effect which can be use as addition therapy for stable COPD.
Methods: The pretest and postest experimental clinical trial was carried out in 40 patients with stable COPD in the pulmonology outpatient clinics of Dr. Moewardi Surakarta and dr. Soehadi Prijonegoro Sragen hospital from 6 January to 6 March 2020. Forty subjects were grouped into treatment group (n=20) receiving standart therapy along with roflumilast 500 mg/day and placebo group (n=20) receiving standart therapy only for 28 days. Decreased inflammation measured by ANC and serum MMP-9, improvement of obstruction measured by % FEV1, and clinic improvement measured by CAT score.
Results: Our finding revealed decreases of ANC and MMP-9 serum in the treatment group, although statistically insignificant (p=0,449), (p= 0,195) respectively. %VEP1 value increased insignificant in the treatment groups (p=0,189). Chronic obstructive pulmonary disease assessment test (CAT) score decreased significantly in the treatment group (p=0.000).
Conclusion: Roflumilast administration reduce inflammation as it can lower not significant ANC, MMP-9 serum, higher not significant %VEP1, and improves the clinical condition of patients with stable COPD based on a decrease in CAT score.Downloads
References
Amin M, Yunus F, Antariksa B, Djajalaksana S, Wiyono WH, Sutoyo DK, editors. PPOK (Penyakit Paru Obstruktif Kronis) diagnosis dan penatalaksanaan. Jakarta: Penerbit Universitas Indonesia; 2016. p. 1-111.
Global Initiative For Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Cape Town: GOLD Science Committee University of Wisconsin; 2019. p. 1-139.
Word Health Organization. Chronic obstructive pulmonary disease (COPD). Desember 2017. [Cited 2019 March 18th]. Available from: www.who.int/respiratory/copd/burden.
Tuder RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest. 2012;122(8):2749-55.
Fooladi AAI, Yazdani S, Nourani MR. in. Ong KC. Ed. Lung and systemic inflammation in COPD, chronic obstructive pulmonary disease – current concepts and practice, 2012. In Tech. [Cited, 2019 November 17th]. Available from:http://www.intechopen.com/books/chronic-obstructive-pulmonary-disease-current-concepts-and-practice/lung-and-systemic-inflammation-in-copd.
Higashimoto Y, Iwata T, Okada M, Satoh H, Fukuda K, Tohda Y, Serum biomarkers as predictors of lung fungtion decline in chronic obstructive pulmonary disease. Respir Med. 2009;103:1231-8.
Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138:16-27.
Ardestani ME, Zaerin O. Role of serum interleukin 6, albumin and c-reactive protein in COPD patients. Tanaffos. 2015;14(2):134-40.
Schuliga M. NF-kappaB signaling in chronic inflammatory airway disease. Biomolecules. 2015;5(3):1266-83.
Cazzola M, Page CP, Calzetta L, Matera MG. Emerging anti-inflammatory strategies for COPD. Eur Respir J. 2012;40:724-41.
Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35:71-86.
Zhang X, Chen Y, Fan L, Ye J, Fan J, Xu X, et al. Pharmacological mechanism of roflumilast in the treatment of asthma–COPD overlap. Drug design, development and therapy. 2018;12:2371-79.
Marin L, Colombo P, Bebawy M, Young PM, Traini D. Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management. Expert opinion on drug delivery. 2011;8(9):1205-20.
Brashier BB, Kodgule R. Risk factors and pathophysiology of chronic obstructive pulmonary disease (COPD). Supplement To JAPI. 2012;60:17-21.
Fukuchi, Y. The aging lung and chronic obstructive pulmonary disease, similarity and difference. Proc Am Thorac Soc.2009;1:570-2.
Sholihah M, Suradi, Aphridasari J. Pengaruh Pemberian Quercetin Terhadap Kadar Interleukin 8 (IL-8) Dan Nilai COPD Assessment Test (CAT) Pasien Penyakit Paru Obstruktif Kronik (PPOK) Stabil. J Respir Indo. 2019;39(2):103-12.
Stockley RA, Mannino D, Barnes PJ. Burden and pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2009;6:524-6.
Barnes PJ. Chronic obstructive pulmonary disease: effects beyond the lung. PloS Med. 2010;7(3):1-4.
Bailey KL, Goraya J, Rennard SL. The role of systemic inflammation in COPD. In: Nici L, ZuWallack, eds. COPD co-morbidities and systemic consequences. New York: Humana Press Springer Science+Business Media; 2012. p.15-30.
Kawamatawong T. Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases. J Thorac Dis. 2017;9(4):1144-54.
Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, et al. The preclinical pharmacology of roflumilast–a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010;23(4):235-56.
Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbröker D, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. 2007;62(12):1081-7.
Linder R, Ronmark E, Pourazar J, Behndig A, Blomberg A, Linberg A. Serum metalloproteinase 9 is related to COPD severity and sympoms-cross-sectional data from a population base cohort-study. Respiratory Research. 2015;16:1-9.
Milara J, Armengot M, Banuls P, Tenor H, Beume R, Artigues E, et al. Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro. Br J Pharmacol 2012;166:2243-62.
Bateman ED, Bousquet J, Aubier M, Bredenbröker D, O’Byrne PM. Roflumilast for asthma: efficacy findings in non-placebo-controlled comparator and dosing studies. Pulm Pharmacol Ther. 2015;35:S11-S19.
Yeadon M, Clarke N, Ward J. Phospodiesterase type 4 (PDE4) inhibition: The search for effective therapy with minimal side effects. In: Bolliger CT, editor. New drugs and targets for asthma and COPD. Switzerland: Karger; 2010. p. 269-78.
Downloads
Additional Files
Published
Issue
Section
License
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
